Skip to main content
SpringerLink
Log in

Be aware that the use of tobacco, cannabinoids and smoking cessation may result in pharmacokinetic interactions with other drugs

  • Drug Reactions and Interactions
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Tobacco smoke and cannabinoids both induce the drug-metabolizing enzymes cytochrome P450 (CYP) 1A1 and CYP1A2, with additive effects when they are used in combination. As a result, tobacco smoking and cannabinoid use, as well as their abrupt cessation, may alter exposure to some drugs. Moreover, the pharmacokinetics of nicotine and cannabinoids may be affected by the concomitant use of other drugs, and CYP2B6 inducers and inhibitors may alter the pharmacokinetics of bupropion, a smoking cessation product. When clinically significant CYP-mediated pharmacokinetic interactions occur, it may be necessary to alter the dose of some drugs (particularly those with a narrow therapeutic index) in order to maintain optimal drug concentrations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Anderson GD, Chan LN. Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products. Clin Pharmacokinet. 2016;55(11):1353–68.

    Article  CAS  PubMed  Google Scholar 

  2. Kim KH, Jahan SA, Kabir E, et al. A review of airborne polycyclic aromatic hydrocarbons (PAHs) and their human health effects. Environ Int. 2013;60:71–80.

    Article  CAS  PubMed  Google Scholar 

  3. Benowitz NL, Hukkanen J, Jacob P 3rd. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol. 2009;192:29–60.

    Article  CAS  Google Scholar 

  4. Obach RS, Ryder TF. Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010;38(8):1381–91.

    Article  CAS  PubMed  Google Scholar 

  5. Lecht S, Haroutiunian S, Hoffman A, et al. Rasagiline: a novel MAO B inhibitor in Parkinson’s disease therapy. Ther Clin Risk Manag. 2007;3(3):467–74.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Hukkanen J, Jacob P 3rd, Peng M, et al. Effect of nicotine on cytochrome P450 1A2 activity. Br J Clin Pharmacol. 2011;72(5):836–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kyaw WT, Nagai M, Kaneta M, et al. Effect of nicotine on the pharmacokinetics of levodopa. Clin Neuropharmacol. 2013;36(2):46–51.

    Article  CAS  PubMed  Google Scholar 

  8. Zevin S, Benowitz NL. Drug interactions with tobacco smoking: an update. Clin Pharmacokinet. 1999;36(6):425–38.

    Article  CAS  PubMed  Google Scholar 

  9. Yousef AM, Arafat T, Bulatova NR, et al. Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. J Clin Pharm Ther. 2008;33(4):439–49.

    Article  CAS  PubMed  Google Scholar 

  10. Gurbel PA, Bliden KP, Logan DK, et al. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol. 2013;62(6):505–12.

    Article  CAS  PubMed  Google Scholar 

  11. Hartter S, Nordmark A, Rose DM, et al. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br J Clin Pharmacol. 2003;56(6):679–82.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Ursing C, von Bahr C, Brismar K, et al. Influence of cigarette smoking on melatonin levels in man. Eur J Clin Pharmacol. 2005;61(3):197–201.

    Article  CAS  PubMed  Google Scholar 

  13. Lind AB, Reis M, Bengtsson F, et al. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. Clin Pharmacokinet. 2009;48(1):63–70.

    Article  CAS  PubMed  Google Scholar 

  14. Jaquenoud Sirot E, Harenberg S, Vandel P, et al. Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression. J Clin Psychopharmacol. 2012;32(5):622–9.

    Article  PubMed  Google Scholar 

  15. Hayashi Y, Watanabe T, Aoki A, et al. Factors affecting steadystate plasma concentrations of enantiomeric mirtazapine and its desmethylated metabolites in Japanese psychiatric patients. Pharmacopsychiatry. 2015;48(7):279–85.

    Article  CAS  PubMed  Google Scholar 

  16. Backman JT, Schroder MT, Neuvonen PJ. Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. Eur J Clin Pharmacol. 2008;64(1):17–24.

    Article  CAS  PubMed  Google Scholar 

  17. Hukkanen J, Jacob P 3rd, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57(1):79–115.

    Article  CAS  PubMed  Google Scholar 

  18. Elkader AK, Brands B, Selby P, et al. Methadone-nicotine interactions in methadone maintenance treatment patients. J Clin Psychopharmacol. 2009;29(3):231–8.

    Article  CAS  PubMed  Google Scholar 

  19. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327–60.

    Article  CAS  PubMed  Google Scholar 

  20. Jiang R, Yamaori S, Takeda S, et al. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci. 2011;89(5–6):165–70.

    Article  CAS  PubMed  Google Scholar 

  21. Agurell S, Carlsson S, Lindgren JE, et al. Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man: assay of cannabinol and cannabidiol by mass fragmentography. Experientia. 1981;37(10):1090–2.

    Article  CAS  PubMed  Google Scholar 

  22. Nadulski T, Pragst F, Weinberg G, et al. Randomized, doubleblind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther Drug Monit. 2005;27(6):799–810.

    Article  CAS  PubMed  Google Scholar 

  23. Benowitz NL, Jones RT. Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism: antipyrine, pentobarbital, and ethanol. Clin Pharmacol Ther. 1977;22(3):259–68.

    Article  CAS  PubMed  Google Scholar 

  24. Chetty M, Miller R, Moodley SV. Smoking and body weight influence the clearance of chlorpromazine. Eur J Clin Pharmacol. 1994;46(6):523–6.

    Article  CAS  PubMed  Google Scholar 

  25. Geffrey AL, Pollack SF, Bruno PL, et al. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246–51.

    Article  CAS  PubMed  Google Scholar 

  26. Jusko WJ, Gardner MJ, Mangione A, et al. Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. J Pharm Sci. 1979;68(11):1358–66.

    Article  CAS  PubMed  Google Scholar 

  27. Stott C, White L, Wright S, et al. A phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of rifampicin, ketoconazole, and omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. Springerplus. 2013;2(1):236.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther. 2004;76(2):178–84.

    Article  CAS  PubMed  Google Scholar 

  29. Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Ther. 2005;27(11):1685–95.

    Article  CAS  PubMed  Google Scholar 

  30. Guzey C, Norstrom A, Spigset O. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. Ther Drug Monit. 2002;24(3):436–7.

    Article  PubMed  Google Scholar 

  31. Shad MU, Preskorn SH. A possible bupropion and imipramine interaction. J Clin Psychopharmacol. 1997;17(2):118–9.

    Article  CAS  PubMed  Google Scholar 

  32. Kennedy SH, McCann SM, Masellis M, et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry. 2002;63(3):181–6.

    Article  CAS  PubMed  Google Scholar 

  33. Fan L, Wang JC, Jiang F, et al. Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation. Eur J Clin Pharmacol. 2009;65(4):403–9.

    Article  CAS  PubMed  Google Scholar 

  34. Ketter TA, Jenkins JB, Schroeder DH, et al. Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol. 1995;15(5):327–33.

    Article  CAS  PubMed  Google Scholar 

  35. Turpeinen M, Tolonen A, Uusitalo J, et al. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2005;77(6):553–9.

    Article  CAS  PubMed  Google Scholar 

  36. Robertson SM, Maldarelli F, Natarajan V, et al. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr. 2008;49(5):513–9.

    Article  CAS  PubMed  Google Scholar 

  37. Palovaara S, Pelkonen O, Uusitalo J, et al. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2003;74(4):326–33.

    Article  CAS  PubMed  Google Scholar 

  38. Lei HP, Yu XY, Xie HT, et al. Effect of St. John’s wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers. Xenobiotica. 2010;40(4):275–81.

    Article  CAS  PubMed  Google Scholar 

  39. Hogeland GW, Swindells S, McNabb JC, et al. Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin Pharmacol Ther. 2007;81(1):69–75.

    Article  CAS  PubMed  Google Scholar 

  40. Loboz KK, Gross AS, Williams KM, et al. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther. 2006;80(1):75–84.

    Article  CAS  PubMed  Google Scholar 

  41. Kharasch ED, Mitchell D, Coles R, et al. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother. 2008;52(5):1663–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Hesse LM, Greenblatt DJ, von Moltke LL, et al. Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers. J Clin Pharmacol. 2006;46(5):567–76.

    Article  CAS  PubMed  Google Scholar 

  43. Feng B, Obach RS, Burstein AH, et al. Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro–in vivo study. Clin Pharmacol Ther. 2008;83(4):567–76.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Ethics declarations

    The article was adapted from Clinical Pharmacokinetics 2016;55(11):1353–68 [1] by employees of Adis/Springer and was not supported by any external funding.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Adis Medical Writers. Be aware that the use of tobacco, cannabinoids and smoking cessation may result in pharmacokinetic interactions with other drugs. Drugs Ther Perspect 33, 339–344 (2017). https://doi.org/10.1007/s40267-017-0410-1

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-017-0410-1

    Search

    Navigation